ArticleStem cell research & therapy2025
Glycyrrhizic acid combined with human adipose-derived MSCs synergistically alleviates the MPP+/MPTP-induced parkinson's disease by inducing autophagy through PI3K/AKT/HIF-1α pathway.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapeutic potential of glycyrrhizic acid in inflammation-related diseases: from HMGB1-oriented molecular insights to preclinical application.Archives of pharmacal research · 2026Review
- Review
- Phytomedicines in preclinical and clinical research on antipsychotics-induced EPS/EPS-like behaviors: therapeutic effects and neurobiological mechanisms.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
aimsEmerging research highlights the considerable therapeutic promise of glycyrrhizic acid (GA) and stem cells used separately for Parkinson's disease (PD). Nevertheless, the combined effects of GA and adipose-derived mesenchymal stem cells (ADSCs) in PD models have not been thoroughly investigated. This research is designed to evaluate the therapeutic potential of GA combined with ADSCs in vitro and in vivo, and to analyze the underlying molecular mechanisms. MAIN
methodsIn vitro experiments were performed in SH-SY5Y cell. In vivo experiments were performed in C57BL/6 mice. KEY
findingsIn comparison to other treatment groups, the combination of GA and ADSCs exhibited improved therapeutic effects in vitro. RNA sequencing analysis revealed involvement of autophagy and the PI3K/AKT/HIF-1α signaling pathway in the treatment. In follow-up research, the combination of GA and ADSCs markedly increased the expression ratios of p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR proteins in vitro following 1-methyl-4-phenylpyridinium (MPP+) exposure. Besides, the combined treatment downregulated the LC3II/LC3I expression ratio and Beclin-1 expression levels while upregulating p62, HIF-1α, and VEGFA expression levels. Similar to 3-MA, results from western blot, transmission electron microscopy (TEM) and immunofluorescence staining (IF) indicated that the combined treatment significantly reduced autophagy. However, treatment with the PI3K inhibitor (LY294002) reversed these increases in the expression ratios of p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR, as well as the levels of p62, HIF-1α, and VEGFA. Moreover, LY294002 significantly impaired the autophagy-suppressing effects of the combination treatment. Finally, the combination of GA and ADSCs ameliorated behavioral deficits and pathological damage to dopaminergic neurons in PD mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). SIGNIFICANCE: The combination of GA and ADSCs displayed remarkable neuroprotective effects in vitro and in vivo. The underlying mechanism involves the regulation of autophagy via the PI3K/AKT/HIF-1α signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.